Structural engineering of a phage lysin that targets Gram-negative pathogens
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Bacterial pathogens are becoming increasingly resistant to antibiotics. As an alternative therapeutic strategy, phage therapy reagents containing purified viral lysins have been developed against Gram-positive organisms but not against Gram-negative organisms due to the inability of these types of drugs to cross the bacterial outer membrane. We solved the crystal structures of a Yersinia pestis outer membrane transporter called FyuA and a bacterial toxin called pesticin that targets this transporter. FyuA is a β-barrel membrane protein belonging to the family of TonB dependent transporters, whereas pesticin is a soluble protein with two domains, one that binds to FyuA and another that is structurally similar to phage T4 lysozyme. The structure of pesticin allowed us to design a phage therapy reagent comprised of the FyuA binding domain of pesticin fused to the N-terminus of T4 lysozyme. This hybrid toxin kills specific Yersinia and pathogenic E. coli strains and, importantly, can evade the pesticin immunity protein (Pim) giving it a distinct advantage over pesticin. Furthermore, because FyuA is required for virulence and is more common in pathogenic bacteria, the hybrid toxin also has the advantage of targeting primarily disease-causing bacteria rather than indiscriminately eliminating natural gut flora.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Johnson, J. R., & Stell, A. L. (2000) · The Journal of Infectious Diseases · doi:10.1086/315217 · Cited by 1,269 · cited 1×
“Given its clear clinical relevance, FyuA has been proposed as a particularly useful target for therapeutic intervention (35), and our hybrid lysin thus provides an FyuA-specific tool to potentially combat bubonic and pneumonic plague as well as various E.”
BackgroundTonB-dependent transporters: regulation, structure, and function
Noinaj, N., Guillier, M., Barnard, & Buchanan, S. K. (2010) · Annual Review of Microbiology · doi:10.1146/annurev.micro.112408.134247 · Cited by 989
Self-citation
Cited by
Applications of Lysozyme, an Innate Immune Defense Factor, as an Alternative Antibiotic
Ferraboschi, P., Ciceri, S., & Grisenti, P. (2021) · Antibiotics · doi:10.3390/antibiotics10121534 · Cited by 448
Engineered Endolysin-Based “Artilysins” To Combat Multidrug-Resistant Gram-Negative Pathogens
Briers, Y., Walmagh, M., Van Puyenbroeck, V., Cornelissen, A., Cenens, W., Aertsen, A., Oliveira, H., Azeredo, J., Verween, G., Pirnay, J.-P., et al. (2014) · mBio · doi:10.1128/mbio.01379-14 · Cited by 421
Porcheron, G., Garénaux, A., Proulx, J., Sabri, M., & Dozois, C. M. (2013) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2013.00090 · Cited by 366
Lood, R., Winer, B. Y., Pelzek, A. J., Diez-Martinez, R., Thandar, M., Euler, C. W., Schuch, R., & Fischetti, V. A. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04641-14 · Cited by 272
Bacteriophages in Natural and Artificial Environments
Batinovic, S., Wassef, F., Knowler, S. A., Rice, D. T. F., Stanton, C. R., Rose, J., Tucci, J., Nittami, T., Vinh, A., Drummond, G. R., et al. (2019) · Pathogens · doi:10.3390/pathogens8030100 · Cited by 253
Metadata
- Authors
- Lukacik, P., Barnard, T. J., Keller, P. W., Chaturvedi, K. S., Seddiki, N., Fairman, J. W., Noinaj, N., Kirby, T. L., Henderson, J. P., Steven, A. C., Hinnebusch, B. J., & Buchanan, S. K.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2012-06-07
- Volume
- 109
- Issue
- 25
- Pages
- 9857-9862
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2011957174
- Cited by
- 155
- References
- 2
- FWCI
- 11.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Structural engineering of a phage lysin that targets Gram-negative pathogens. https://app.cochat.ai/papers/10.1073/pnas.1203472109
- The paper
- Lukacik, P., Barnard, T. J., Keller, P. W., Chaturvedi, K. S., Seddiki, N., Fairman, J. W., Noinaj, N., Kirby, T. L., Henderson, J. P., Steven, A. C., Hinnebusch, B. J., & Buchanan, S. K. (2012). Structural engineering of a phage lysin that targets Gram-negative pathogens. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1203472109
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.